Skip to content

GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis

The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01201135
Acronym
GDF 15
Enrollment
80
Registered
2010-09-14
Start date
2010-09-30
Completion date
2011-09-30
Last updated
2010-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Dyserythropoietic Anemia Type I, Patients With Thalassemia Intermedia,

Brief summary

Patients with thalassemia intermedia, congenital dyserythropoietic anemia type I , and sideroblastic anemia were found to express very high levels of serum GDF15, and this contributed to the inappropriate suppression of hepcidin with subsequent secondary iron overload.The aim of our present study is to asses the levels of GDF15 and hepcidin in patients with Sickle cell disease and hereditary spherocytosis

Detailed description

The identification of the ferroportin/hepcidin axis has allowed the effect of erythroid activity on iron balance to be studied and has created the basis for better defining the erythroid regulators. In iron-loading anemias, ineffective erythropoiesis suppresses hepcidin production, which result in dysregulating iron homeostasis. Miller and co-workers showed that release of cytokines like growth differentiation factor 15 (GDF15) during the process of ineffective erythropoiesis inhibits hepcidin production, thus defining a molecular link between ineffective erythropoiesis, suppression of hepcidin production and parenchymal iron loading.

Interventions

None listed

Sponsors

Wolfson Medical Center
Lead SponsorOTHER_GOV

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* non

Exclusion criteria

* non

Design outcomes

Primary

MeasureTime frame
GDF 15year

Secondary

MeasureTime frame
Hepcidineyear

Contacts

Primary ContactGhoti Hossam, doctor
drghoti123@yahoo.com035028110

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026